PhII Study of Concurrent Chemoradiotherapy With Weekly Docetaxel, Carboplatin and Radiation Therapy Followed by Consolidation Chemotherapy With Docetaxel and Carboplatin for Locally Advanced Inoperable Non-small Cell Lung Cancer (NSCLC)
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 入组人数
- 63
- 试验地点
- 15
- 主要终点
- Overall Survival
研究概览
简要总结
RATIONALE: Because of its success in advanced NSCLC both as a single agent and in combination with other chemotherapeutics, it is reasonable to investigate the efficacy and toxicity of docetaxel as a multimodality regimen in this patient population. Docetaxel at a dose of 20 mg/m2 appears to be a well-tolerated "weekly" dose when combined with either cisplatin 25 mg/m2 20-22 or carboplatin area under the curve (AUC) 2 23-25 concomitant with radiation therapy.
PURPOSE: To explore the potential benefits of the radiosensitizing effects of weekly docetaxel/carboplatin/radio therapy concurrent therapy followed full dose systemic docetaxel/carboplatin consolidation therapy on overall response rate, survival, progression-free survival, safety and toxicity in patients with locally advanced NSCLC.
详细描述
OBJECTIVES:
Primary
- To determine the overall survival (0S) for advanced NSCLC patients receiving concurrent chemoradiotherapy with weekly docetaxel, carboplatin and radiation therapy followed by two cycles of consolidation chemotherapy with docetaxel and carboplatin.
Secondary
- To determine the overall response rate in patients treated with this regimen.
- To determine the time to disease progression in patients treated with this regimen.
- To assess the safety and tolerability of this regimen in these patients.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients must voluntarily sign and date an informed consent before the initiation of any study procedures
- •Patients must have non-metastatic, inoperable, Stage IIIA or IIIB histologically or cytologically documented NSCLC without evidence of malignant pleural effusion
- •Patients must not have received any prior systemic chemotherapy, thoracic radiotherapy or surgical resection for treatment of NSCLC
- •Patients must have at least one site of unidirectionally measurable disease
- •Patients must be ≥ 3 weeks from a formal exploratory thoracotomy
- •Patients must have a Radiation Oncology and Medical Oncology consult and approval prior to study entry
- •Patients must be ≥ 18 years of age
- •Women of childbearing potential must have a negative baseline serum pregnancy within 7 days prior to Week 1, Day 1 and must not be breast feeding.
- •Women of childbearing potential and men with a sexual partner of child bearing potential must use an effective method of contraception beginning prior to study entry, for the duration of the study participation and for a minimum of 3 months after the last dose of chemotherapy.
- •Patients must have adequate hepatic, renal, lung and bone marrow function as defined below:
- •Absolute neutrophil count (ANC) > 1,500/mm3
- •Hemoglobin > 9.0 gm/dL
- •Creatinine < 1.5
- •Platelets > 100,000/mm3
- •Total bilirubin within normal limits (WNL)
- •AST or ALT and Alkaline Phosphatase must be within the range allowing for eligibility, as per chart on page 10 of the protocol.
- •Calculated CrCl > 50 ml/min (via Cockroft-Gault formula).
- •Forced expiratory volume in 1 second (FEV 1) > 800 ml
排除标准
- •Known hypersensitivity to drugs formulated with polysorbate 80
- •Peripheral neuropathy Grade ≥
- •Wet stage IIIB (documented malignant pleural effusion) or stage IV NSCLC
- •Previous chemotherapy or radiation therapy
- •Any concomitant malignancy, brain metastasis or uncontrolled, clinically significant medical or psychiatric disorder
- •Pregnant or nursing women
- •A greater than or equal to 10% weight loss over the past 3 months
研究组 & 干预措施
Therapeutic Intervention
干预措施: Carboplatin (Drug)
Therapeutic Intervention
干预措施: Docetaxel (Drug)
Therapeutic Intervention
干预措施: radiation therapy (Radiation)
结局指标
主要结局
Overall Survival
时间窗: 14.95 months (average duration, on study date to off-study date)
Months from on-study to expired/last date known alive.
次要结局
- Overall Response Rate(on-study date to date of best response)
- Time to Disease Progression(on-study date to date of progression)
- Number of Participants With Adverse Events by Grade(30 days after last treatment.)
研究者
Vicki Keedy, MD
Assistant Professor of Medicine; Clinical Director, Sarcoma Program; Assistant Medical Director, Clinical Trials Shared Resource; Medical Oncologist
Vanderbilt-Ingram Cancer Center